Management Team

David G.P. Allan, Chairman and Chief Executive Officer & Director

Vera Belaoussoff, H.B.Sc., M.Sc., Director, Preclinical and Scientific Policy

Christopher J. Burns, Ph.D., Director, Research, YM BioSciences Australia

Melanie DuBois, B.Sc., Director, Quality Assurance

Gary Floyd, Vice President, Operations

Nick Glover, Ph.D., President and Chief Operating Officer

David A. Kennard, Ph.D., M.B.A., Director, European Operations

Andrew Macdonald, B.B., B.Sc., President, YM BioSciences Australia

Leonardo Viana Nicacio, M.D., Director, Clinical Affairs

Ali Raza, M.D., President, AeroLEF® Division

German Rogés, M.D., Ph.D., Country Manager

Vincent Salvatori, Ph.D., President and Chief Operating Officer, CIMYM BioSciences Inc.

Gregg Smith, Ph.D., M.B.A., Director, Drug Development and Operations, YM BioSciences Australia

Sean Thompson, B.Sc., Vice President, Corporate Development and General Manager, IntelliMab™

Len Vernon, B.Sc., C.A., Vice President, Finance and Administration

Mark Vincent, M.D., Director, Investigational Oncology

Andrew Yoshioka, B.Sc., Vice President, AeroLEF® Division



David G.P. Allan
Chairman and Chief Executive Officer & Director
Mr. Allan has been Chief Executive Officer of the Corporation since April 1998 and Chairman of the board of directors of the Corporation since 1994.  In addition, Mr. Allan is a Director of Synthemed Inc. (medical devices), USA and DiaMedica Inc. (diabetes therapeutics), Canada. In 1992 he founded the Knowledge-Based Industries Group of a Canadian investment banking firm, organized as the first in Canada involved in financing, analyzing and creating strategic alliances for life sciences and information technology companies, where he was Executive Director until 1998. Mr. Allan was formerly a governor of The Toronto Stock Exchange, a member of the Awards Selection Committee for the Networks of Centres of Excellence in Canada, working group Chair of the Ontario Biotechnology Advisory Board and a member of the Board of Trustees for the Ontario College of Art and Design. Mr. Allan is currently a member of BIOTECanada's Emerging Companies Advisory Board.

return to top

Vera Belaoussoff, H.B.Sc., M.Sc.
Director, Preclinical and Scientific Policy
Ms. Belaoussoff has been with the Corporation since 2009. Prior to joining YM, Ms. Belaoussoff was engaged in providing consulting services to the biotechnology industry, with a focus on business development and capital markets communication. Ms. Belaoussoff was a healthcare analyst for eight years in the financial services industry, most recently on the buy-side with Scotia Cassels Investment Management where she covered the North American healthcare industry. Prior to that, she was a healthcare analyst in the brokerage industry and participated in over $80 million of biotech financing. Ms. Belaoussoff also spent eight years in basic research in the field of schizophrenia, and has her M.Sc. (Molecular Biology) from York University in Toronto, and an Honour's B.Sc. (Genetics) from the University of Manitoba.

return to top

Christopher J. Burns, Ph.D.
Director, Research
YM BioSciences Australia
Dr. Burns received a PhD in Organic Chemistry from the University of Melbourne in 1989 and undertook postdoctoral research at Penn State University, USA. In 1991, he joined Pfizer Central Research in the UK and after five years returned to Australia to take up a position as Research Fellow in the School of Chemistry, University of Sydney. After two years he joined Sydney-based biotech company, Ambri Pty Ltd as Chemistry Project Leader. He joined Cytopia in 2001 to establish and lead the Medicinal Chemistry team and was appointed Director, Research in 2005.

return to top

Melanie DuBois, B.Sc.
Director, Quality Assurance
Ms. DuBois joined the Corporation in 2008 after a year in the capacity of consultant in Quality Assurance to the Corporation. From 1989 to 2006, Ms. DuBois was employed by GlaxoSmithKline in Mississauga, Ontario in increasing levels of Quality-related positions including Manager, North American Pharmaceutical Development Quality Assurance. She earned a Bachelor of Technology in Laboratory Sciences from Ryerson Polytechnical University in 1987, brings with her over 20 years of experience in the Quality area, and has a strong knowledge of current Good Manufacturing Practices and Quality Systems.

return to top

Gary Floyd
Vice President, Operations
YM BioSciences USA Inc.
Mr. Floyd is a seasoned executive with an extensive background in the global pharmaceutical industry. Most recently, he served as President of Pharmavene LLC, a pharmaceutical consulting firm. Prior to his position at Pharmavene, Mr. Floyd was Senior Vice President, Worldwide Logistics and Procurement at Aventis Behring where he was responsible for Supply Chain Management of the company's global business. This included sales and operations planning, global purchasing and biopharmaceutical operations systems management and development. He also held the position of Senior Vice President, Worldwide Business Systems at Aventis Behring. Mr. Floyd has held various executive positions in the pharmaceutical industry, including Senior Vice President, Worldwide Industrial Operations at Centeon LLC and Vice President, Sales and Marketing, The Americas and Vice President, Operations at Armour Pharmaceutical Company where he managed a multipurpose manufacturing plant with 800 employees. Mr. Floyd is a Vietnam Veteran, having served in the United States Army where he received the Bronze Star and the Army Commendation Medal for Meritorious Service. He received his BA in Chemistry and Zoology from Olivet Nazarene University.

return to top

Nick Glover, Ph.D.
President and Chief Operating Officer
Dr. Glover joined the Corporation in 2010. Dr. Glover was formerly President and Chief Executive Officer of Viventia Biotech Inc. where he led the strategic development of a novel monoclonal antibody discovery platform, advancing three clinical products including a Phase III antibody for the treatment of advanced head and neck cancer. He has been responsible for all aspects of biotherapeutic development, including GMP manufacturing, and has taken products from discovery, through preclinical development and into global registration clinical trials, with a specific focus in oncology. Prior to joining Viventia, Dr. Glover was an investment manager for a leading venture capital firm. Dr. Glover has a significant background in business development, concluding numerous licensing and partnering agreements in both academia and industry, with organizations such as the University of Cambridge, Micromet AG and Merck KGaA. He has authored or co-authored over 50 scientific and medical papers, abstracts, proceedings and book chapters, and his research has been published in prestigious and respected sources including the Journal of the American Chemical Society, Biochemistry, Current Opinion in Drug Discovery & Development, and Medical Oncology. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, an M.Sc. in Chemistry from the University of British Columbia, and a Ph.D. in Chemistry from Simon Fraser University.

return to top

David A. Kennard, Ph.D., M.B.A.
Director, European Operations
Dr. Kennard has been with the Corporation since 2004. Prior to joining, he was CEO of the pain development company NeuroTargets.  Dr. Kennard spent eight years prior to that as the COO of SR Pharma, a publicly traded UK-based biotechnology company which developed therapeutic vaccines.  He was also with GlaxoSmithKline in clinical research and regulatory affairs and subsequently in strategic planning.  Dr. Kennard holds an MBA and Ph.D. from the London University, and is a member of the Royal Pharmaceutical Society of Great Britain.

return to top

Andrew Macdonald, B.B., B.Sc.
President
YM BioSciences Australia
Mr. Macdonald joined Cytopia as Chief Financial Officer / Company Secretary in August 2005. He has 20 years of financial and commercial experience working in Australia, the United States and the United Kingdom. Before joining Cytopia, he previously held the roles of Finance Director and Company Secretary in Biota Holdings Ltd, Richard Oliver International Pty Ltd, Willis Ltd and as VP, Finance, and later CEO, of Sharinga Networks Inc.

return to top

Leonardo Viana Nicacio, M.D.
Director, Clinical Affairs
Dr. Nicacio, a medical oncologist joined the Corporation in 2008. Dr. Nicacio was the Medical Manager of Eurofarma Laboratorios Ltda in Brazil and was responsible for the clinical development of the oncologic, antiinffective, and biotech portfolio. He received his Medical degree in Brazil and did his residency at Hospital Sirio Libanes in Sao Paulo, BR. Prior to joining the Corporation he was an advisor of drug development for Brazilian pharmaceutical companies and received training in molecular and clinical research in the US. He is currently a member of the American Society of Clinical Oncology.

return to top

Ali Raza, M.D.
President, AeroLEF® Division 
Dr. Raza joined the Corporation in 2008. He was with AstraZeneca for 14 years, ultimately heading up the Clinical Sciences Department at the Company's Global Headquarters for Cardiovascular R&D in Sweden.  He has led teams responsible for registration of a number of molecules including b-blockers, ACE inhibitors and statins.  He has spent the last five years in the biotech arena in senior leadership positions, latterly serving as President of Sosei, Japan.  He holds a degree in Biochemistry from Manchester University, completed his post-graduate research at Imperial College, London and holds a medical degree from London University.

return to top

German Rogés, M.D., Ph.D.
Country Manager
Dr. Roges joined the Corporation in 1998. He had previously worked in the Tropical Medicine Institute "Pedro Kourí" from Havana, Cuba as a Virologist and Cooperation Manager. He worked also as a Visiting Lecturer at the University of Guyana while on assignment with the Pan-American Health Organization from 1987-1989. Dr. Roges has authored and co-authored numerous scientific publications in peer review journals and sat on two Advisory Committees of the Cuban Ministry of Health. He graduated as an M.D. from the Superior Institute of Health Sciences in Cuba and in 1986 received the title of First Degree Specialist on Microbiology from the Cuban Ministry of Health. Dr. Roges attended fellowships at the Pasteur Institute in Paris and the University of Southampton, UK. He also received the accreditation of Clinical Research Professional (CCRP) from SOCRA.

return to top

Vincent Salvatori, Ph.D.
President and Chief Operating Officer
CIMYM BioSciences Inc.
Dr. Salvatori has been with the Corporation since 2002, and is an experienced drug development executive with an accomplished background in the pharmaceutical and biotechnology industry.   He has more than 20 years of experience in all aspects of drug development, corporate operations and external collaborations. He most recently held the position of Senior Vice President of Clinical Operations for Bioniche Life Sciences Inc. He was formerly at StressGen Biotechnologies Corporation where he held the positions of Chief Operating Officer and Vice President of Research and Development, subsequently appointed to Senior Vice President of the company. In this capacity he was responsible for corporate operations, strategic management and clinical/regulatory development. Prior to joining StressGen, Dr. Salvatori was the Senior Director of Program Management at QLT PhotoTherapeutics Inc. and various positions at Boehringer Ingelheim (Canada) Ltd.

return to top

Gregg Smith, Ph.D., M.B.A.
Director, Drug Development and Operations
YM BioSciences Australia
Dr. Smith was appointed Director, Drug Development and Operations in 2006 after joining Cytopia (now YM BioSciences Australia) in August 2005 as Head of Drug Development. Dr. Smith has responsibility for the formal preclinical and clinical development activities for CYT387 and CYT997 as well as operations for the Australian subsidiary. He has over ten years’ drug development experience and has managed all aspects of five small-molecule development programmes from the discovery/development interface to Phase I and II trials.  Dr. Smith holds a PhD from the University of Queensland, School of Pharmacy and an MBA from Chifley Business School.  He is also a registered Pharmacist in Victoria.

return to top

Sean Thompson, B.Sc.
Vice President, Corporate Development and General Manager, IntelliMab™
Mr. Thompson is responsible for all aspects of corporate development for YM, including licensing, identifying targets for M&A and development partnerships.  He has a solid background in clinical development and big Pharma marketing experience, and was previously Director of Clinical Research for YM.  Prior to YM he worked for Roche, sitting on the Global Business Team in virology, and was Clinical Research Manager. Prior to Roche, he was a Clinical Scientist for SmithKline Beecham developing products for oncology, respiratory and CNS disorders. He is currently Vice Chair of the BIOTECanada Health Policy Advisory Board, a member of the Ontario Institute for Cancer Research Industry Advisory Board and was previously a Board member for Variation Biotechnologies Inc. Mr. Thompson holds a Bachelor of Science degree from the University of Waterloo.

return to top

Len Vernon, B.Sc., C.A.
Vice President, Finance and Administration
Mr. Vernon earned a B.Sc. in 1968 and was awarded his C.A. in 1972 with Clarkson Gordon & Co. (now Ernst & Young).  He has held senior financial positions with a number of organizations both public and private.  Prior to joining YM in 1997, Mr. Vernon was an independent consultant working with senior management in a variety of industries.  Prior to 1992 he was Vice-President, Finance and Administration of Unitel Inc. (now MTS Allstream Inc.) a major Canadian telecommunications company.

return to top

Mark Vincent, M.D.
Director, Investigational Oncology
Dr. Vincent has been with the Corporation since 2000.  In addition to his position at YM as Director, Investigational Oncology and Chair, Scientific Advisory Board, he is an Associate Professor, Dept. of Oncology, with the University of Western Ontario and Staff Medical Oncologist at the London Regional Cancer Program, in London, Canada.

return to top

Andrew Yoshioka, B.Sc.
Vice President, AeroLEF® Division
Mr. Yoshioka joined the Corporation in May 2005 with the acquisition of DELEX Therapeutics Inc. which he had been with since 2001 as Director of Product Development. He has over 23 years of pharmaceutical experience. Previously, Mr. Yoshioka held various positions at GlaxoSmithKline, SmithKline Beecham Pharma, Bencard Allergy Laboratories, and Boehringer Ingelheim (Canada) Ltd. and has submitted and negotiated various types of registration files as a Regulatory Affairs Associate/Regulatory Marketing Associate. Mr. Yoshioka has a B.Sc. in Biochemistry from McGill University.

return to top